Abstract
Post liver transplant recurrence in patients with hepatocellular carcinoma: not necessarily the end of the road!
Highlights
Liver transplantation (LT) is accepted as the best curative option for hepatocellular carcinoma (HCC) in patients with decompensated liver disease as it achieves oncological clearance, and treats the underlying chronic liver disease (CLD)[1]
In patients accepted for living donor liver transplantation (LDLT) beyond the conventional size-number criteria, even after HCC recurrence, an aggressive approach using multimodality therapy, when possible, aids in further prolongation of survival
From our prospectively maintained database of 2,363 LDLT’s (2005 to mid 2018 so as to have a minimum follow up of 2 years post LDLT at the time of data analysis), we studied outcomes in 435 histologically confirmed cirrhosis and HCC (HCC-cirr) patients (18.4% of all LDLTs performed during this period)
Summary
Liver transplantation (LT) is accepted as the best curative option for hepatocellular carcinoma (HCC) in patients with decompensated liver disease as it achieves oncological clearance, and treats the underlying chronic liver disease (CLD)[1]. This holds true when selection of patients for LT adheres to either the conventional Milan[2] and UCSF[3] criteria, or other expanded criteria[4,5,6,7,8,9] which have yielded similar long term outcomes. Results using these systemic agents are far from satisfactory, and they are known to prolong survival only by a few months
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.